How Plant Polyphenols May Slow the Arterial Damage Behind Heart Attacks and Stroke

Atherosclerosis, the slow silent narrowing of the arteries that underlies most heart attacks and strokes, has long been framed as a plumbing problem: too much cholesterol, too much plaque, too little room for blood to flow. Modern vascular biology tells a far more intricate story. A new narrative review published in Molecular Biology Reports by Arup Dey, Manish Kumar Gautam and colleagues at Assam down town University and the All India Institute of Ayurveda pulls together decades of experimental, clinical and epidemiological work to argue that the disease is best understood as a chronic inflammatory condition, and that a family of plant compounds known as dietary polyphenols may intervene at nearly every step of its molecular choreography. The review, which synthesizes evidence on compounds ranging from resveratrol and quercetin to catechins, curcumin and anthocyanins, is both an encouraging map of cardioprotective mechanisms and a sober reminder of how far the field still is from proving real clinical benefit.

The starting point of the review is the pathogenesis of atherosclerosis itself. The disease begins when the endothelium, the single layer of cells lining the arterial wall, becomes dysfunctional under the combined assault of high blood pressure, disturbed blood flow, smoking, diabetes and oxidized lipids. Damaged endothelial cells express adhesion molecules such as ICAM-1 and VCAM-1, which allow circulating monocytes to stick to the vessel wall and squeeze between them into the intima. There, the monocytes mature into macrophages that engulf modified low-density lipoprotein particles, swell into foam cells and release a cocktail of pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha. Vascular smooth muscle cells migrate and proliferate, stabilizing or destabilizing the growing plaque, and the resulting lesions can rupture catastrophically, triggering the clots that cause myocardial infarction and stroke. Every one of these steps, the authors emphasize, is a potential point of pharmacological or nutritional intervention.

Oxidative stress sits at the center of this cascade. Reactive oxygen species generated by dysfunctional endothelial cells, mitochondria and inflammatory enzymes promote the oxidation of LDL cholesterol, converting it into the oxidized LDL that macrophages find irresistible. Oxidative stress also inactivates nitric oxide, the endothelial gas molecule that keeps vessels dilated and inflammation suppressed. The body’s first-line antioxidant defenses, superoxide dismutase, catalase and glutathione peroxidase, normally hold these reactive species in check, and experimental work cited in the review shows that boosting these enzymes in mice inhibits smooth muscle proliferation and offsets pro-atherogenic gene expression in human endothelial cells. Yet the history of antioxidant therapy in cardiology is humbling: large randomized trials of vitamin E and C supplementation, including the ASAP study, the HOPE trial and the GISSI-Prevenzione trial, largely failed to reduce cardiovascular events. That failure is precisely why the field has shifted its attention to polyphenols, which act less like blunt radical scavengers and more like modulators of cellular signaling networks.

The review’s mechanistic core describes how specific polyphenols engage the master switches of vascular inflammation. Nuclear factor-kappa B, or NF-κB, is the transcription factor that switches on the genes for adhesion molecules and cytokines in endothelial cells and macrophages; the mitogen-activated protein kinase pathways feed into the same inflammatory program. Quercetin, for example, has been shown in macrophage models to disrupt the association between phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88, thereby dampening both MAPK/AP-1 and IKK/NF-κB-driven production of inflammatory mediators. On the protective side of the redox balance, polyphenols activate the Keap1-Nrf2 pathway, which induces the expression of endogenous antioxidant enzymes through the antioxidant response element. Anthocyanins, the pigments in berries, have been reported to activate Nrf2-ARE signaling as a modulator of redox homeostasis, while natural products broadly are increasingly recognized as activators of Nrf2 signaling with cardiovascular protective potential.

Resveratrol, the stilbene famous from red grapes, illustrates how deeply these compounds can reach into cellular metabolism. Structural studies reviewed by the authors show that resveratrol allosterically stimulates SIRT1, the NAD-dependent deacetylase linked to cellular stress resistance and longevity, and downstream effects extend to AMP-activated protein kinase, a central regulator of energy metabolism. In the context of cholesterol handling, resveratrol has been associated with improved cholesterol metabolism and with enhanced expression of the transporters ABCA1 and ABCG1, which export cholesterol from macrophage foam cells in the first step of reverse cholesterol transport. Catechins from green tea, particularly epigallocatechin gallate, and curcumin from turmeric each carry their own portfolio of anti-inflammatory, antioxidant and lipid-modulating actions documented across in vitro and animal studies. The picture that emerges is not one molecule, one target, but a network pharmacology in which dietary compounds nudge several atherogenic processes simultaneously.

What does the human evidence show? Clinical studies and meta-analyses reviewed by the authors suggest potential improvements in endothelial function, lipid profiles, blood pressure and inflammatory biomarkers after polyphenol-rich dietary interventions. Cocoa flavanols have produced some of the most consistent results: randomized trials, including the Flaviola Health Study, found that flavanol intake improved endothelial function and Framingham Risk Score in healthy adults, and a dose-response meta-analysis of randomized trials confirmed a relationship between cocoa flavanol intake and endothelial function. Olive oil polyphenols have their own track record: a randomized trial published in Annals of Internal Medicine showed that polyphenol-rich olive oil favorably modified heart disease risk factors, and later work found improvements in lipoprotein particle atherogenic ratios. In the PREDIMED trial substudy, higher polyphenol intake from a Mediterranean diet was associated with decreased inflammatory biomarkers related to atherosclerosis, and a crossover trial of hydroxytyrosol and punicalagin supplementation improved early markers of asymptomatic atherosclerosis in adults.

Yet the review is careful to flag the caveats, and they are substantial. Findings across clinical studies remain heterogeneous, and most of the supportive evidence rests on surrogate outcomes, such as flow-mediated dilation, oxidized LDL levels or C-reactive protein, rather than hard endpoints like myocardial infarction or cardiovascular death. Some trials are strikingly negative: a randomized placebo-controlled crossover trial found that resveratrol did not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects, even as a separate triple-blind trial reported that a grape extract containing resveratrol decreased oxidized LDL and apolipoprotein B in patients on primary prevention. Inter-individual variability looms large, since human studies show wide differences in how people metabolize and absorb polyphenolic compounds, driven by genetics, gut microbiota composition and dietary context. The authors conclude that clinical efficacy in atherosclerosis management remains uncertain and call for well-designed, long-term studies to clarify therapeutic relevance, optimal dosing and safety.

Two emerging strategies may help close the gap between promising mechanisms and clinical reality. The first is bioavailability engineering. Polyphenols are notoriously poorly absorbed, extensively metabolized and rapidly cleared, which limits the concentrations reaching arterial tissue. Nano-delivery systems, including liposomal and polymeric nanoparticle formulations, are being developed to protect these compounds through digestion and enhance their uptake; a recent randomized double-blind trial of a double-layered nano-liposomal curcumin formulation demonstrated enhanced bioavailability in humans, and pharmacokinetic studies of novel resveratrol formulations are following a similar path. The second strategy targets the gut microbiota, which transforms many parent polyphenols into metabolites that may actually be the biologically active species. Reviews of probiotic and phenolic approaches to atherosclerosis suggest that microbiota-targeted interventions could amplify cardioprotective effects, although the authors note that clinical efficacy for both nano-formulations and microbiota-directed approaches remains to be established.

Safety, too, deserves attention. Polyphenols are not automatically benign at high doses: they can interact with medicines, and reviews have catalogued possible side effects and drug interactions, while meta-analyses of curcumin and turmeric supplementation have examined effects on liver function with mixed findings. The review’s overall verdict is measured but constructive: antioxidants and dietary polyphenols may provide complementary approaches for cardiovascular risk reduction, best delivered through polyphenol-rich dietary patterns such as the Mediterranean diet rather than high-dose isolated supplements, and always alongside, not instead of, established therapies like statins and blood pressure control. For a disease that remains the leading cause of death worldwide, the message is that the chemistry of everyday plant foods is genuinely interesting at the molecular level, and that the next decade of long-term clinical trials will determine whether that molecular interest can be translated into fewer heart attacks and strokes.

Subject of Research: Molecular mechanisms by which dietary polyphenols influence atherosclerosis, endothelial dysfunction, oxidative stress and vascular inflammation

Article Title: Dietary polyphenols in atherosclerosis: a review of molecular mechanisms, endothelial dysfunction, oxidative stress, and vascular inflammation

Article References: Dietary polyphenols in atherosclerosis: a review of molecular mechanisms, endothelial dysfunction, oxidative stress, and vascular inflammation. (n.d.). https://doi.org/10.1007/s11033-026-12914-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12914-4

Keywords: atherosclerosis, dietary polyphenols, endothelial dysfunction, oxidative stress, vascular inflammation, NF-kappaB, Nrf2, resveratrol, quercetin, curcumin, gut microbiota, cardiovascular disease